Show simple item record

dc.contributor.authorLipowska-Bhalla, Grazyna
dc.contributor.authorGilham, David E
dc.contributor.authorHawkins, Robert E
dc.contributor.authorRothwell, Dominic G
dc.date.accessioned2012-08-29T16:03:21Z
dc.date.available2012-08-29T16:03:21Z
dc.date.issued2012-07
dc.identifier.citationTargeted immunotherapy of cancer with CAR T cells: achievements and challenges. 2012, 61 (7):953-62 Cancer Immunol Immunotheren_GB
dc.identifier.issn1432-0851
dc.identifier.pmid22527245
dc.identifier.doi10.1007/s00262-012-1254-0
dc.identifier.urihttp://hdl.handle.net/10541/240459
dc.description.abstractThe adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer immunology, immunotherapy : CIIen_GB
dc.titleTargeted immunotherapy of cancer with CAR T cells: achievements and challenges.en
dc.typeArticleen
dc.contributor.departmentClinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.en_GB
dc.identifier.journalCancer Immunology Immunotherapyen_GB
html.description.abstractThe adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies.


This item appears in the following Collection(s)

Show simple item record